Abstract
Localizing the sites of infection in the body is possible in nuclear medicine using a variety of radiopharmaceuticals that target different components of the infective and inflammatory cascade. Gamma(γ)-emitting agents such as [67Ga]gallium citrate were among the first tracers used, followed by development of positron-emitting tracers like 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG). Though these tracers are quite sensitive, they have limited specificity for infection due to their concentration in sites of non-infective inflammation. White blood cells (WBC) labelled with γ or positron emitters have higher accuracy for differentiating the infective processes from the non-infective conditions that may show positivity with tracers such as 18F-FDG. We present a pictorial review of potential clinical applications of PET/CT using 18F-FDG labelled WBC.
Introduction
Infection is a pathological process that can present with a wide range of manifestations based on the site, extent, severity and the pathogen that is inciting the disease process. Clinical symptoms and signs may help in localizing the site of infection with the help of laboratory parameters such as leukocyte count, erythrocyte sedimentation rate and C-reactive protein which serve as markers for infection and associated inflammation. Anatomical imaging techniques including X-ray, CT and MRI are useful in infection imaging, based on the site of disease. However, these imaging methods are not sensitive for the detection of infective processes at early stages before anatomical changes set in. 1
Nuclear medicine functional imaging techniques can help in overcoming these shortcomings. Infection imaging in nuclear medicine involves use of both γ and positron-emitting radiopharmaceuticals. [67Ga]gallium citrate and 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) are sensitive for infection but are non-specific, as they may accumulate in sites of sterile non-infective inflammation which is frequently seen in patients who have undergone a surgical procedure or following insertion of a prosthetic device. 2 This limitation can be overcome by more specific agents that target specific processes such as radiolabelled antibiotics (such as ciprofloxacin and fluconazole), radiolabelled monoclonal antibodies targeted against specific receptors on the surface of leukocytes, radiolabelled cytokines or chemokines and labelled white blood cells (WBC). 1,3
Radiotracers available for WBC labelling include gamma-emitting agents such as [111In]In-oxine 4 and [99mTc]Tc-HMPAO, 5 and positron-emitting agents such as 18F-FDG. Basic equipment and time required for the WBC labelling procedure is similar for different radiotracers. However, the cost of the radiotracer will vary from one region to another. Institutions equipped with a medical cyclotron may prefer to use 18F-FDG produced in-house, rather than purchase [111In]In-oxine or HMPAO kits. 6–9 Despite the higher specificity of radiolabelled WBC, the main disadvantage of gamma-emitting agents such as indium-111 was their poor imaging characteristics. 2 The protocol for a labelled WBC study using gamma-emitting agents involves an early image at 0.5–1 h, a delayed scan at 3–4 h and a late image at 20–24 h. 4,5 This allows for sufficient background tracer activity clearance from the blood pool and better visualization of lesions. Delayed imaging with 18F-FDG-labelled WBC is not possible due to the shorter half-life of 18F. However, the superior imaging characteristics of 18F-FDG ensure that the diagnostic performance of 18F-FDG-labelled WBC is comparable to [111In]In-oxine labelled WBC. 7 In infective foci with low neutrophil response, the lack of delayed images may result in false-negative results and studies with WBC labelled with longer lived positron emitters may be required to clarify this issue.
18F-FDG-labelled WBC labelling procedure
Bhattacharya et al 8 modified the in-vitro method of radiolabelling of WBC to allow for labelling with 18F-FDG under sterile aseptic conditions. While all WBC labelling methods follow the same basic principle, there are significant differences in the successive steps for labelling WBCs using [99mTc], [111In] or 18F-FDG. The final labelling efficiency varies widely depending on which of these tracers / methods is used. As reported by Meyer et al 10 , the study by Bhattacharya et al 8 used the lowest amount of 18F-FDG with the highest labelling efficiency. In this method, about 40 ml of the patient’s blood is drawn into a heparinized syringe. The red blood cells are removed by sedimentation and the WBC rich plasma is then centrifuged to separate the pellet containing WBCs. This WBC pellet is reconstituted in heparinized normal saline and incubated at 37°C with 18F-FDG for labelling the WBCs. The labelled cells are reconstituted with cell-free plasma obtained during centrifugation and the reconstituted preparation injected into the patient. The labelling efficiency by this method was found to be 81 ± 17%. 8 Though the labelling efficiency with 18F-FDG was lower in other studies, the diagnostic performance was comparable to other γ-emitting agents. 10 Radiochemical purity has to be ensured before injection as the presence of higher quantities of free 18F-FDG may lead to physiological uptake in organs such as the brain (Figure 1) and to a decrease in specificity due to free 18F-FDG uptake by non-infective inflammatory processes.
About 148–185 MBq of 18F-FDG-labelled WBCs are injected into the patient and optimal imaging time is 120 min post-injection. The field of imaging can be whole body or limited to the region of interest only. The normal biodistribution of 18F-FDG-labelled WBCs is shown in the positron emission tomography (PET) image in Figure 1. In a meta-analysis done by Meyer et al, [18F]FDG-labelled WBC PET/CT was found to have a higher diagnostic accuracy than conventional modalities such as CT or MRI and 18F-FDG PET/CT. An area of focal increased tracer uptake is interpreted as positive for infection on 18F-FDG-labelled WBC PET/CT. However, no definite cut-off of standardized uptake value (SUV) was identified to reliably suggest presence of infection in this meta-analysis of five studies evaluating SUV parameters in labelled 18F-FDG-labelled WBC PET/CT. 10
Potential clinical indications
Due to its high sensitivity, 18F-FDG PET/CT is the first-line diagnostic imaging modality for evaluating patients with fever of unknown origin as this symptom can be caused by infection or malignancy. 12 However, radiolabelled WBC imaging has been reported to be useful in localizing the site and extent of infections in a wide range of conditions with a higher specificity. The clinical indications investigated with 18F-FDG-labelled WBC to date include infections in renal cysts, in peripancreatic fluid collections in cases of pancreatitis, as well as diagnosing prosthesis-related infections and exclusion of diagnosis of osteomyelitis. 10
Figure 2 shows the use of 18F-FDG-labelled WBC PET/CT contributing to the diagnosis of skull base osteomyelitis in a diabetic patient with recurrent middle ear infection in a post-surgical patient. The advantage of 18F-FDG-labelled WBC PET/CT in this condition is the ability to delineate active infection from post-surgical inflammatory changes. The lack of normal physiological uptake of 18F-FDG-labelled WBC in the brain parenchyma as compared to 18F-FDG enhances visual assessment of tracer uptake at the site of skull base infection.
Figures 3–5 show the potential utility of 18F-FDG-labelled WBC PET/CT in patients with infections of cardiac implants and following cardiovascular surgical procedures. 18F-FDG-labelled WBC PET/CT can diagnose the presence of infection and can also localize the site and extent of the infection, thereby, directing the patient towards appropriate management procedures. 13 18F-FDG-labelled WBC PET/CT can also predict whether a collection seen in the abdominal cavity is infected or sterile based on the results that have been seen in patients with peripancreatic fluid collection. 8 Figure 6 shows one such patient with infected peripancreatic collection. 18F-FDG-labelled WBC PET/CT may also have a potential role in assessing the extent and severity of colitis (Figure 7). The advantage over 18F-FDG PET/CT is the complete absence of any normal physiological bowel uptake that is often seen with 18F-FDG.
Figures 8 and 9 show the potential role of 18F-FDG-labelled WBC PET/CT in assessing infection in patients with orthopedic infections – both following the removal of implants and with implants in-situ. The advantage of 18F-FDG-labelled WBC PET/CT in this condition lies in the fact that a conventional three-phase radionuclide bone scan or 18F-FDG PET/CT may show significant false-positive activity in bones with residual reactive changes following orthopedic surgery. 14 This role can also be potentially extended to patients with diabetic cellulitis (Figure 10) where 18F-FDG-labelled WBC PET/CT can help in ruling out presence of any infective bone involvement. 15 Though the 18F-FDG-labelled WBC study is only used in a research setting in some centers, it is performed as a part of routine clinical management in our institute. However, all the patients undergoing the procedure, including those mentioned in this review, signed an informed consent before undergoing the procedure.
Potential false-positives and false-negatives
Imaging using 18F-FDG-labelled WBC PET/CT is based on the principle of enhanced vascular permeability and chemokine-induced rapid neutrophil aggregation at sites of acute inflammation which leads to accumulation of radiolabelled WBCs. It does not involve direct imaging of the pathogenic organisms, and so false-positive results can be seen in sites of acute non-infectious inflammation with neutrophil accumulation such as inflammatory bowel disease (Figure 11). Other causes of a false-positive study include apparent increase in tracer activity due to anatomical factors such as blood flow confined to a small volume as in a case of collapsed lung (Figures 6 and 11), poor labelling of the WBC with 18F-FDG resulting in non-specific accumulation of free 18F-FDG and extravasation from hemorrhagic lesions. 10
The potential false negatives include chronic infection and inflammation which has a predominant lymphocyte and macrophage infiltration, prior exposure to effective antibiotic therapy and in immunosuppressed hosts with poor immune response. Vertebral osteomyelitis is also seen to have a lower grade of radiolabelled WBC accumulation. 10
Drawbacks of 18F-FDG-labelled WBC PET/CT
Though 18F-FDG-labelled WBC PET/CT has numerous potential indications as discussed, there are some drawbacks as compared to 18F-FDG PET/CT such as requirement of skilled technical expertise for labelling, increase in total duration of the investigation to account for the time required for the labelling procedure, potential costs involved with the required setup for labelling, need to maintain sterility during handling of blood products and the inherent risks associated with injection of blood and blood products. 16 Eventually, the short half-life of 18F does not allow delayed images acquisition beyond 120 min which is possible using gamma-emitting agents. In-vitro studies using newer agents labelled with long-lived positron emitting agents such as copper-64 and zirconium-89 are being investigated to enable delayed imaging. 17,18
Conclusion
18F-FDG-labelled WBC PET/CT might be of interest for diagnosing the presence of infection in suspected cases and for assessing the extent and severity of infection which can help in guiding appropriate management decisions. However, routine clinical use is currently not recommended due to limited data available in the literature and drawbacks associated with the labeling procedure.
Contributor Information
Venkata Subramanian Krishnaraju, Email: venkat.hc@gmail.com.
Harmandeep Singh, Email: drharmandeepsingh@gmail.com.
Rajender Kumar, Email: drrajender2010@gmail.com.
Sarika Sharma, Email: sarika2j@gmail.com.
Bhagwant Rai Mittal, Email: brmittal@yahoo.com.
Anish Bhattacharya, Email: anishpgi@yahoo.co.in.
REFERENCES
- 1. Salmanoglu E, Kim S, Thakur ML. Currently available radiopharmaceuticals for imaging infection and the Holy Grail. Semin Nucl Med 2018; 48: 86–99. doi: 10.1053/j.semnuclmed.2017.10.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation--current and emerging clinical applications. Clin Radiol 2015; 70: 787–800. doi: 10.1016/j.crad.2015.03.010 [DOI] [PubMed] [Google Scholar]
- 3. Goldsmith SJ, Vallabhajosula S. Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications. Semin Nucl Med 2009; 39: 2–10. doi: 10.1053/j.semnuclmed.2008.08.002 [DOI] [PubMed] [Google Scholar]
- 4. Roca M, de Vries EFJ, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (111)In-oxine. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging 2010; 37: 835–41. doi: 10.1007/s00259-010-1393-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. de Vries EFJ, Roca M, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging 2010; 37: 842–8. doi: 10.1007/s00259-010-1394-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Osman S, Danpure HJ. The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B 1992; 19: 183–90. doi: 10.1016/0883-2897(92)90006-K [DOI] [PubMed] [Google Scholar]
- 7. Rini JN, Bhargava KK, Tronco GG, Singer C, Caprioli R, Marwin SE, et al. PET with FDG-labeled leukocytes versus scintigraphy with 111In-oxine-labeled leukocytes for detection of infection. Radiology 2006; 238: 978–87. doi: 10.1148/radiol.2382041993 [DOI] [PubMed] [Google Scholar]
- 8. Bhattacharya A, Kochhar R, Sharma S, Ray P, Kalra N, Khandelwal N, et al. PET/CT with 18F-FDG-labeled autologous leukocytes for the diagnosis of infected fluid collections in acute pancreatitis. J Nucl Med 2014; 55: 1267–72. doi: 10.2967/jnumed.114.137232 [DOI] [PubMed] [Google Scholar]
- 9. Dumarey N, Egrise D, Blocklet D, Stallenberg B, Remmelink M, del Marmol V, Marmol del V, et al. Imaging infection with 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med 2006; 47: 625–32. [PubMed] [Google Scholar]
- 10. Meyer M, Testart N, Jreige M, Kamani C, Moshebah M, Muoio B, et al. Diagnostic performance of PET or PET/CT using 18F-FDG labeled white blood cells in infectious diseases: a systematic review and a bivariate meta-analysis. Diagnostics 2019; 9: 60. doi: 10.3390/diagnostics9020060 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Forstrom LA, Dunn WL, Mullan BP, Hung JC, Lowe VJ, Thorson LM. Biodistribution and dosimetry of [(18)F]fluorodeoxyglucose labelled leukocytes in normal human subjects. Nucl Med Commun 2002; 23: 721–5. doi: 10.1097/00006231-200208000-00004 [DOI] [PubMed] [Google Scholar]
- 12. Kouijzer IJE, Mulders-Manders CM, Bleeker-Rovers CP, Oyen WJG. Fever of unknown origin: the value of FDG-PET/CT. Semin Nucl Med 2018; 48: 100–7. doi: 10.1053/j.semnuclmed.2017.11.004 [DOI] [PubMed] [Google Scholar]
- 13. Yilmaz S, Aliyev A, Ekmekcioglu O, Ozhan M, Uslu L, Vatankulu B, et al. Comparison of FDG and FDG-labeled leukocytes PET/CT in diagnosis of infection. Nuklearmedizin 2015; 54: 262–71. doi: 10.3413/Nukmed-0724-15-02 [DOI] [PubMed] [Google Scholar]
- 14. Aksoy SY, Asa S, Ozhan M, Ocak M, Sager MS, Erkan ME, et al. Fdg and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection. Eur J Nucl Med Mol Imaging 2014; 41: 556–64. doi: 10.1007/s00259-013-2597-2 [DOI] [PubMed] [Google Scholar]
- 15. Rastogi A, Bhattacharya A, Prakash M, Sharma S, Mittal BR, Khandelwal N, et al. Utility of PET/CT with fluorine-18-fluorodeoxyglucose-labeled autologous leukocytes for diagnosing diabetic foot osteomyelitis in patients with Charcot's neuroarthropathy. Nucl Med Commun 2016; 37: 1253–9. doi: 10.1097/MNM.0000000000000603 [DOI] [PubMed] [Google Scholar]
- 16. Dibble EH, Yoo DC, Baird GL, Noto RB. FDG PET/CT of infection: should it replace labeled leukocyte scintigraphy of inpatients? AJR Am J Roentgenol 2019; 213: 1358–65. doi: 10.2214/AJR.18.20475 [DOI] [PubMed] [Google Scholar]
- 17. Bhargava KK, Gupta RK, Nichols KJ, Palestro CJ. In vitro human leukocyte labeling with (64)Cu: an intraindividual comparison with (111)In-oxine and (18)F-FDG. Nucl Med Biol 2009; 36: 545–9. doi: 10.1016/j.nucmedbio.2009.03.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Man F, Khan AA, Carrascal-Miniño A, Blower PJ, T.M. de Rosales R. A kit formulation for the preparation of [89Zr]Zr(oxinate)4 for PET cell tracking: White blood cell labelling and comparison with [111In]In(oxinate)3. Nucl Med Biol 2020; 90-91: 31–40. doi: 10.1016/j.nucmedbio.2020.09.002 [DOI] [PMC free article] [PubMed] [Google Scholar]